Medizentrum Essen Borbeck
- Address
- lock Available on a paid plan
Cardiovascular Diseases
Medizentrum Essen Borbeck is conducting studies that aim to improve outcomes for patients with cardiovascular disease, focusing on conditions such as atherosclerosis, elevated lipoprotein(a), and hypertension. The trials evaluate novel lipid‑lowering agents and blood‑pressure medicines to lower the risk of major cardiac events.
- Atherosclerotic cardiovascular disease
- Elevated lipoprotein(a)
- Hypertension
- Resistant hypertension
- Heart failure with preserved ejection fraction
- Major adverse cardiovascular events
A total of 38 trials are active at the site, supported by five investigators, making it a key centre for cardiovascular research in the region.
Digestive System Diseases
The centre is exploring new therapeutic options for digestive system disorders, including functional bowel conditions and acute infections. Research aims to relieve symptoms and improve quality of life for patients with irritable bowel syndrome and acute bronchitis‑related cough.
- Irritable bowel syndrome (diarrhoea‑predominant)
- Acute bronchitis
- Acute pharyngitis
- Chronic bronchitis
Across the 38 ongoing trials, five investigators contribute to advancing digestive health at this hospital.
Hormonal Diseases
Studies at the site target hormonal and metabolic disorders such as type 2 diabetes and obesity, assessing both weight‑loss strategies and glucose‑control therapies. The goal is to determine safe and effective approaches for long‑term metabolic health.
- Type 2 diabetes
- Obesity
- Overweight without diabetes
- Hypercholesterolemia
- Metabolic syndrome
With 38 clinical studies underway and a dedicated team of five investigators, the hospital serves as a hub for hormonal disease research in Europe.
Immune System Diseases
The facility is evaluating preventive and therapeutic solutions for immune‑mediated infections, including vaccines against respiratory syncytial virus, influenza, and herpes zoster. These trials measure immune response durability and protection rates in older adults.
- Respiratory syncytial virus (RSV) infection
- Influenza
- Herpes zoster
- Human metapneumovirus
A total of 38 trials and five investigators focus on strengthening immunity and reducing infection‑related morbidity at Medizentrum Essen Borbeck.
Nervous System Diseases
Research efforts are directed toward improving brain health in patients with post‑COVID cognitive impairment. The studies test natural extracts and other interventions to enhance memory and attention after viral infection.
- Cognitive impairment associated with post‑COVID‑19 syndrome
- Neurocognitive decline
The site’s portfolio of 38 trials, overseen by five investigators, includes dedicated neuroscience investigations.
Nutritional and Metabolic Diseases
Clinical work at the centre addresses nutritional and metabolic conditions such as obesity, overweight, and related metabolic risk factors. Trials evaluate novel agents for weight reduction and metabolic regulation.
- Obesity
- Overweight
- Type 2 diabetes
- Metabolic syndrome
- Elevated lipoprotein(a)
With 38 active studies and a team of five investigators, the hospital is a regional leader in metabolic disease research.
Otorhinolaryngologic Diseases
The institution conducts trials aimed at relieving symptoms of allergic rhinitis and related ENT conditions. Immunotherapy and symptom‑relief lozenges are among the interventions being tested.
- Seasonal allergic rhinitis
- Rhinoconjunctivitis induced by house dust mite
- Acute pharyngitis
- Allergic rhinitis with or without asthma
A total of 38 clinical trials, supported by five investigators, focus on improving upper‑airway health at this site.
Respiratory Tract Diseases
Ongoing investigations target respiratory illnesses such as chronic obstructive pulmonary disease, acute bronchitis, and viral lower‑respiratory infections. The aim is to reduce exacerbations and improve lung function.
- Chronic obstructive pulmonary disease (COPD)
- Acute bronchitis
- Chronic bronchitis
- Respiratory syncytial virus lower‑respiratory disease
- Human metapneumovirus infection
The site supports 38 trials with five investigators, positioning it as a key centre for respiratory research in Germany.
Virus Diseases
The hospital is actively testing vaccines and antiviral strategies for viral diseases, especially those affecting older adults. Studies measure vaccine efficacy, safety, and long‑term immune protection.
- Respiratory syncytial virus (RSV)
- Influenza A and B
- Human metapneumovirus
- Herpes zoster virus
With 38 trials underway and a team of five investigators, Medizentrum Essen Borbeck contributes significantly to viral disease prevention research.
Immune System Phenomena
Research programs examine immune response mechanisms to assess how new vaccines stimulate humoral immunity and how immunotherapies modulate disease activity. The focus is on durability of protection and safety profiles.
- Humoral immune response to RSV vaccine
- Immunogenicity of influenza vaccine
- Immune modulation in allergic rhinitis
- Safety of immune‑targeted therapies
The centre’s portfolio of 38 active trials, guided by five investigators, underlines its commitment to advancing immunology research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 11 therapeutic areas and 15 of 137 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 133 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 12 by active trials.
- 1Eli Lilly & Co.2active
lock +11 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Eli Lilly & Co.6trials
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medizentrum Essen Borbeck
lock Showing 1 of 43 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of ALN-4324 in Overweight to Obese Healthy Volunteers and Patients With Type 2 Diabetes Mellitus | Alnylam Pharmaceuticals Inc. | Phase I/II | Not Recruiting | Mar 2026 | — |
IMP list
lock Showing 1 of 137 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E | 3 | Unknown | 2021-02-22 | 2024-08-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.